New and updated preclinical data presented at the Society for Immunotherapy of Cancer's Annual Meeting
in Boston, by: Actym, Calidi, Cantargia, Cytovia, Enara Bio, Immunome, Leap, Lyell Immunopharma, TCR2.
Dimethylfumarate (DMF) is largely used for treating multiple sclerosis (MS), but about 61% of DMF-treated patients develop lymphopenia, with its consequent associated risks. Biomarkers for monitoring treatment efficacy with DMF in patients with MS would be helpful in this field.
Spanish researchers at Hospital Universitario La Paz have aimed to investigate the correlation between extracellular vesicles (EVs) from the immune and nervous system with the diagnosis and disease activity of multiple sclerosis (MS). EVs were isolated and collected from 86 patients with MS and 29 healthy controls from their neurons, oligodendrocytes and B and T lymphocytes.
Researchers from Bern University Hospital and University of Bern presented data from a case study that identified the presence of anti-neurochondrin antibodies as a potential biomarker of primary autoimmune cerebellar ataxia (PACA).
Selenophosphate synthetase 1 (SEPHS1) plays an essential role in the metabolism of selenium and has ATPase activity that synthesizes selenophosphate from ATP and selenide. Researchers have hypothesized the potential involvement of SEPHS1 in genetic disorders. They presented a series of case reports involving 9 individuals with heterozygous missense variants in the SEPHS1 gene; all these variants resided in the C-terminal domain or near the AIR synthase-related domain of the gene.
Inhibition of emerging polyclonal on-target acquired resistance mutations remains a critical unmet need in the treatment of fibroblast growth factor receptor 2 (FGFR2)-driven tumors. In the current study, researchers from Tyra Biosciences Inc. presented the preclinical characterization of a novel FGFR1/2/3 inhibitor, TYRA-200, being developed for the treatment of cancer.
Neuromyelitis optica-related disorder (NMORD) consists of a spectrum of diseases characterized by recurrent optic neuritis and/or myelitis, with most cases being associated with a pathogenic antibody against aquaporin-4 (AQP4-Abs) or antibodies targeting the myelin oligodendrocyte glycoprotein (MOG-Abs).
Multiple sclerosis (MS) is an inflammatory disease affecting the central nervous system that causes damage to myelin, neurons and axons, and which results in neurodegeneration. Identification of useful blood biomarkers for MS is still a challenge.
Duality Biologics (Suzhou) Co. Ltd. has presented data describing the discovery and preclinical results of DB-1303, an antibody-drug conjugate containing a trastuzumab biosimilar targeting HER2 (BAT0606), an exatecan derivative payload with topoisomerase I inhibitory activity (P1003) and an enzymatic ally cleavable tetrapeptide-maleimide-linker (payload-linker named L101P1003).
Sequencing of a total of 16 individuals from 4 multiplex families representing rare and diverse anorectal malformation (ARM) types, as well as 3 surgically resected tissue specimens, resulted in the identification of a novel paternally inherited heterozygous CDX2 variant [c.722A>G (p.Glu241Gly)].